MSD closed 2023 with a turnover of 55.5 billion euros, 1% more than in 2022, when it obtained sales of 54.7 billion euros. The pharmaceutical company...
Vithas and MSD have formed an alliance to enhance patient care, especially in cancer treatment. The collaboration focuses on innovation, research, and education, coinciding with the...
MSD has released its 2021/2022 Environmental, Social and Governance (ESG) Progress Report. The report highlights the company's performance and progress in its four main ESG areas:...